DOSa, NCT04668300: Oleclumab and Durvalumab for the Treatment of Recurrent, Refractory, or Metastatic Sarcoma |
|
|
| Recruiting | 2 | 75 | US | Durvalumab, Imfinzi, Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide with Human Monoclonal MEDI4736 Kappa-chain, Dimer, MEDI-4736, MEDI4736, Oleclumab, Anti-CD73 Monoclonal Antibody MEDI9447, MEDI9447 | M.D. Anderson Cancer Center, National Cancer Institute (NCI) | Metastatic Angiosarcoma, Metastatic Dedifferentiated Liposarcoma, Metastatic Osteosarcoma, Recurrent Angiosarcoma, Recurrent Dedifferentiated Liposarcoma, Recurrent Osteosarcoma, Refractory Dedifferentiated Liposarcoma, Refractory Osteosarcoma | 06/24 | 06/24 | | |
